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AbstrAct
Objective The relationship of anticoagulation therapies 
with stroke severity and outcomes have been well 
documented in the literature. However, none of the 
previous research has reported the relationship of atrial 
fibrillation (AF)/anticoagulation therapies with urinary tract 
infection (UTI), pneumonia and length of stay in hyperacute 
stroke units (HASUs). The present study aimed to evaluate 
AF and anticoagulation status in relation to early outcomes 
in 1387 men (median age=75 years, IQR=65–83) and 
1371 women (median age=83 years, IQR=74–89) 
admitted with acute ischaemic stroke to HASUs in Surrey 
between 2014 and 2016.
Methods We conducted this registry-based, prospective 
cohort study using data from the Sentinel Stroke National 
Audit Programme. Association between AF anticoagulation 
status with severe stroke on arrival (National Institutes 
of Health Stroke Scale score ≥16), prolonged HASU 
stay (>3 weeks), UTI and pneumonia within 7 days of 
admission, severe disability on discharge (modified Rankin 
Scale score=4 and 5) and inpatient mortality was assessed 
by logistic regression, adjusted for age, sex, hypertension, 
congestive heart failure, diabetes and previous stroke.
results Compared with patients with stroke who are 
free from AF, those with AF without anticoagulation 
had an increased adjusted risk of having more severe 
stroke: 5.8% versus 14.0%, OR=2.4 (95% CI 1.6 to 3.6, 
P<0.001), prolonged HASU stay: 21.5% versus 32.0%, 
OR=1.4 (1.0–2.0, P=0.027), pneumonia: 8.2% versus 
19.1%, OR=2.1 (1.4–2.9, P<0.001), more severe disability: 
24.2% versus 40.4%, OR=1.6 (1.2–2.1, P=0.004) and 
mortality: 9.3% versus 21.7%, OR=1.9 (1.4–2.8, P<0.001), 
and AF patients with anticoagulation also had greater 
risk for having UTI: 8.6% versus 12.3%, OR=1.9 (1.2–3.0, 
P=0.004), pneumonia: 8.2% versus 11.5%, OR=1.6 (1.1–
2.4, P=0.025) and mortality: 9.7% versus 21.7%, OR=1.9 
(1.4–2.8, P<0.001). The median HASU stay for stroke 
patients with AF without anticoagulation was 10.6 days 
(IQR=2.8–26.4) compared with 5.8 days (IQR=2.3–17.5) 
for those free from AF (P<0.001).
conclusions Patients with AF, particularly those without 
anticoagulation, are at increased risk of severe stroke, 
associated with prolonged HASU stay and increased risk of 
early infection, disability and mortality.
IntrOductIOn
Each year, about 6.7 million people die of 
stroke worldwide, accounting for 11.9% of 
all deaths.1 Stroke results in adverse health 
consequences including physical disability 
and cognitive impairment,2–4 which imposes 
enormous burdens on patients, their carers 
as well as social and healthcare systems.5 6 
Patients with existing comorbidities such as 
diabetes and cardiovascular diseases including 
coronary heart disease, poorly controlled 
hypertension or congestive heart failure 
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strengths and limitations of this study
 ► The strengths of the present study include its large 
homogenous cohort of patients derived from one 
of the largest National Health Service regions in 
England.
 ► The analysis was robustly adjusted for age and 
sex, as well as major chronic conditions known 
to associate with stroke including hypertension, 
congestive heart failure, diabetes and previous 
stroke.
 ► The data were collected by healthcare providers for 
the patients using national Sentinel Stroke National 
Audit Programme protocol.
 ► Although data are derived only from Surrey, it is 
likely to be representative of the rest of the UK as 
stroke prevalence is similar to that of the UK.
 ► The study did not collect information on types of 
oral anticoagulants and international normalised 
ratio. Information on the duration of anticoagulation 
treatment for individual patients was also not 
available, but it is likely to be closely related to their 
age.
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(CHF) have an increased risk of stroke, but atrial fibril-
lation (AF) remains the biggest risk factor.7 8 Although 
outcomes for stroke patients have improved significantly 
in the UK since the introduction of organised hyperacute 
stroke unit (HASU) care provided by multidisciplinary 
teams,9 10 the elderly and those who have chronic health 
conditions continue to have increased risk of mortality 
and disability, as well as time to recovery requiring longer 
stay in hospital after a stroke.11–13 The relationship of anti-
coagulation therapies with stroke severity and outcomes 
have been well documented in the literature.14–16 
However, none of the previous research has reported the 
relationship of AF/anticoagulation therapies with urinary 
tract infection (UTI), pneumonia and length of stay in 
HASU.
The present study aimed to evaluate the relationship of 
patients with AF and their anticoagulation status on the 
severity of stroke on admission, length of stay in HASU, 
UTI and pneumonia within the first week in hospital, 
early disability on discharge and inpatient mortality.
MethOds
study design, patients and setting
We conducted this registry-based, prospective cohort 
study using data from the Sentinel Stroke National Audit 
Programme (SSNAP), which is the national register of 
stroke care in England and Wales. Data were collected 
prospectively from the time of admission up to 6 months 
after stroke and validated by stroke teams and entered 
into the SSNAP database via a secure web interface. 
These data comprise clinical characteristics and care 
quality of patients admitted to all acute care hospitals 
in England and Wales with acute ischaemic stroke or 
primary intracerebral haemorrhage.12 We used an anony-
mised extract of a total of 3309 patients from Surrey, a 
relatively stable and homogenous population, who were 
admitted to four HASUs within the county (one of the 
largest National Health Service (NHS) regions in the 
England). The hospitals, Ashford and St Peter’s (n=1038), 
Frimley Park (n=1010), Royal Surrey County (n=612) and 
Epsom (n=649), were surveyed between January 2014 
and February 2016. Twenty-two patients were admitted 
twice, and two patients were admitted three times. For 
the purpose of analysis, data from the first admission for 
these 24 patients who were admitted multiple times were 
used.
SSNAP has approval from the Confidentiality Advisory 
Group of the Health Research Authority to collect patient 
data under section 251 of the NHS Act 2006. No addi-
tional ethical approval was sought.
sociodemographic factors and medical history
Data were collected for sociodemographic factors 
including age at arrival, sex and ethnicity, as well as 
medical history including AF, hypertension, CHF, 
diabetes mellitus, previous stroke and drug history. In 
addition, details of new-onset AF cases as well as UTI and 
pneumonia acquired in hospital within 7 days of admis-
sion were documented by the stroke team comprising 
consultants and stroke nurse specialists, including anti-
coagulation treatment from the point of admission to 
discharge.
diagnosis of stroke and severity
Stroke was diagnosed based on clinical presentation 
and brain CT scan as guided by the National Institute 
for Health and Care Excellence.17 The severity of stroke 
symptoms was assessed by the National Institutes of Health 
for Stroke Scale (NIHSS) with score range from no symp-
toms to severe stroke symptoms (NIHSS score=0 to 42).
disability and mortality
Degree of disability or dependence in daily activities were 
assessed by a modified Rankin Scale (mRS), ranging from 
no symptoms to severe symptoms (mRS score=0 to 5) and 
mortality (mRS score=6).
categorisation of variables
Dichotomisation was applied for hypertension, CHF 
and diabetes according to the presence of history of 
the condition or not while age was dichotomised at the 
median value (<79 and ≥79 years). AF and anticoagula-
tion status were categorised into four groups: free from 
AF, AF with anticoagulation, AF without anticoagulation 
and AF unsuitable for anticoagulation. Severity of stroke 
and disability were dichotomised into two groups: no 
symptoms to moderate symptoms (NIHSS score <16 and 
mRS score <4) and moderately severe to severe (NIHSS 
score ≥16 and mRS score=4 and 5). Prolonged stay in 
HASU was defined as patients who stayed in a HASU >3 
weeks (upper fourth quartile of length of stay).
statistical analysis
Of the 3309 patients collected in the database, we anal-
ysed 2758 (83.3%) patients presented with ischaemic 
stroke and the remaining 518 (15.7%) patients with 
haemorrhagic stroke, and 33 (1.0%) patients who were 
unspecified were excluded. The frequency of patients 
with AF using anticoagulation before developing an 
ischaemic stroke was assessed by cross-tabulation and χ2 
tests. Most variables had no missing data, which were 
handled in analysis using a ‘listwise deletion of missing 
data’ approach.18 Independent t-tests were performed to 
compare differences between two groups and analysis of 
variance (ANOVA) between three or more groups, with 
post hoc analysis where applicable. Multivariable logistic 
regression was performed to assess the risk of moder-
ately severe to severe stroke on arrival and disability on 
discharge, inpatient mortality after stroke and prolonged 
stay in HASU (dependent variables) from comorbidities 
including AF, hypertension, CHF, diabetes and previous 
stroke (independent variables). Two logistic regression 
models were conducted: the first model was unadjusted, 
and the second was adjusted for age, sex and comorbidi-
ties. Analyses were performed using SPSS V.22.0. The null 
hypothesis was rejected when P<0.05.
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Table 1 Distribution of 2758 patients admitted with acute 
ischaemic stroke to hospitals in Surrey between January 
2014 and February 2016
Median IQR
Age of men (years) 75.0 65.0–83.0
Age of women (years) 83.0 74.0–89.0
n Proportion (%)
Men:women 1387:1371 50.3:49.7
Caucasian: mixed race, 
black, Asian and other ethnic 
populations: not stated
2544:180:34 92.2:6.6:1.2
First stroke: recurrent stroke 2123:635 77.0:23.0
AF 564 20.4*
  AF with anticoagulation 230 40.8†
  AF without anticoagulation 260 46.1†
  AF not suitable for 
anticoagulation
74 13.1†
Hypertension 1446 52.4
CHF 171 6.2
Diabetes 463 16.8
Stroke severity on arrival
  No stroke symptoms (NIHSS 
score: 0)
368 13.3
  Minor stroke (NIHSS score: 1–4) 1092 39.6
  Moderate stroke (NIHSS score: 
5–15)
930 33.7
  Moderate to severe stroke 
(NIHSS score: 16–20)
195 7.1
  Severe stroke (NIHSS score: 
21–42)
173 6.3
Modified Rankin Scale (mRS) on 
discharge
  No symptoms (mRS score: 0) 682 24.7
  No significant disability (mRS: 1) 489 17.7
  Slight disability (mRS score: 2) 377 13.7
  Moderate disability  
(mRS score: 3)
362 13.1
  Moderately severe disability 
(mRS score: 4)
284 10.3
  Severe disability (mRS score: 5) 130 4.7
  Dead (mRS score: 6) 333 12.1
*Proportion relative to the total number of all patients in the present 
study (n=2758).
†Proportion relative to the number of patients with AF (n=564).
AF, atrial fibrillation; CHF, congestive heart failure; mRS, modified 
Rankin Scale; NIHSS, National Institutes of Health for Stroke Scale.
Figure 1 Distribution of patients against severity of stroke 
on admission based on NIHSS score. NIHSS, National 
Institutes of Health for Stroke Scale.
results
Admissions for stroke were almost equally distributed 
between men (50.3%) and women (49.7%), with the 
onset of the first stroke 6.5 years (95% CI 5.5 to 7.5, 
P<0.001) earlier in men. Table 1 shows that there were 
77.0% of patients presented with first stroke and 23.0% 
with recurrent stroke. Most patients were white Cauca-
sians (92.2%) with the remaining 6.6% comprises mixed 
race, black, Asian and other ethnic populations and 1.2% 
not stated. On arrival, 546 (20.4%) patients had a history 
of AF, in whom 40.8% were treated in the community with 
an anticoagulant, while 46.1% were untreated, although 
13.1% had been considered for anticoagulation and 
deemed unsuitable by their healthcare providers. Also on 
arrival, 7.1% of patients had moderate to severe stroke 
symptoms (NIHSS score=16–20) and 6.3% had severe 
symptoms (NIHSS=21–42). The remainder had no symp-
toms (13.3%, NIHSS=0), minor (39.6%, NIHSS=1–4) 
or moderate (33.7%, NIHSS=5–15) symptoms; a more 
detailed analysis of NIHSS scores is shown in figure 1. 
On discharge, 10.3% and 4.7% of the original patients, 
respectively, had moderately severe (mRS score=4) or 
severe (mRS score=5) symptoms. The rate of inpatient 
mortality was 12.1% (table 1).
Baseline characteristics of patients in different catego-
ries of AF and anticoagulation status are shown in table 2. 
The median age of patients without AF were 77 years old, 
while those with AF were between 83 and 84 years old. 
Hypertension, CHF and moderate to severe stroke were 
more commonly observed among patients with AF than 
those free of AF.
Patients free from AF had significantly less severe stroke 
on admission as reflected by a lower NIHSS score (F=21.8, 
P<0.001) and disability on discharge as indicated by a lower 
mRS score (F=20.9, P<0.001) than patients with AF of any 
anticoagulation status (with anticoagulation, without 
anticoagulation or unsuitable for anticoagulation in the 
community) (figure 2). ANOVA with post hoc analysis by 
least significant difference tests showed that NIHSS score 
on arrival (figure 2A) and mRS on discharge (figure 2B) 
were significantly lower (P<0.01) for those free from AF 
compared with any of the other three groups of patients 
with AF (with anticoagulation, without anticoagulation 
or unsuitable for anticoagulation). The NIHSS score for 
those with AF who were treated with anticoagulant was 
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Table 2 Baseline characteristics of patients admitted with ischaemic stroke according the AF and anticoagulation status
Non-AF
(n=2194)
AF with anticoagulation
(n=230)
AF without 
anticoagulation
(n=260)
AF not suitable for 
anticoagulation
(n=74)
Median IQR Median IQR Median IQR Median IQR
Age (years) 77.0 66.0–85.0 83.0 77.0–88.0 84.0 77.0–90.0 84.0 78.8–88.2
n % n % n % n %
Men:women 1133:1061 51.6:48.4 111:119 48.3:51.7 106:154 40.8:59.2 37:37 50.0:50.0
Hypertension 1093 49.8 142 61.7 160 61.5 51 68.9
CHF 105 4.8 28 12.2 10 13.5 171 6.2
Diabetes 364 16.6 44 19.1 41 15.8 14 18.9
Moderate to severe 
stroke on arrival 
(NIHSS score: ≥16)
114 5.2 17 7.4 36 13.8 6 8.1
AF, atrial fibrillation; CHF, congestive heart failure; NIHSS, National Institutes of Health for Stroke Scale.
Figure 2 Box plots showing AF and anticoagulation status in relation to stroke severity on arrival indicated by NIHSS score 
(A) and severity of disability on discharge indicated by mRS score (B). ANOVA showed significant group differences (P<0.001), 
therefore post hoc least significant difference tests were performed to compare NIHSS score between those †free from AF 
(no AF) and other three AF groups of different anticoagulation status, and between *AF with anticoagulation (AF-treated) and 
AF without anticoagulation (AF-untreated) groups. Box plots represent median and IQR; whiskers represent the 5th and 95th 
percentiles. AF, atrial fibrillation; ANOVA, analysis of variance; mRS, modified Rankin Scale; NIHSS, National Institutes of Health 
for Stroke Scale.
also lower than that of those with AF who were not treated 
with (P=0.011) or considered unsuitable for anticoagula-
tion (P=0.023).
Table 3 shows that compared with patients with stroke 
who were free of AF, those with AF but not anticoagu-
lated had an increased adjusted risk of having more 
severe stroke: 5.8% versus 14.0%, OR=2.4 (95% CI 1.6 
to 3.6, P<0.001), prolonged HASU stay: 21.5% versus 
32.0%, OR=1.4 (95% CI 1.0 to 2.0, P=0.027), pneu-
monia: 8.2% versus 19.1%, OR=2.1 (95% CI 1.4 to 2.9, 
P<0.001), more severe disability: 24.2% versus 40.4%, 
OR=1.6 (95% CI 1.2 to 2.1, P=0.004) and mortality: 
9.3% versus 21.7%, OR=1.9 (95% CI 1.4 to 2.8, P<0.001). 
Patients with AF with anticoagulation also had greater 
risk than those free of AF for having UTI: 8.6% versus 
12.3%, OR=1.9 (95% CI 1.2 to 3.0, P=0.004), pneumonia: 
8.2% versus 11.5%, OR=1.6 (95% CI 1.1 to 2.4, P=0.025) 
and mortality: 9.7% versus 21.7%, OR=1.9 (95% CI 1.4 to 
2.8, P<0.001).
The median length of stay in HASU of 5.8 days 
(IQR=2.3–17.5 days) for patients with stroke who were 
free of AF. In comparison, the corresponding values were 
10.6 days (IQR=2.8–26.4 days) for patients with stroke 
with AF without anticoagulant (P<0.001) and 9.8 days 
(IQR=4.0–30.0 days) for stroke patients who were deemed 
unsuitable for anticoagulation (P=0.010), while anticoag-
ulation in patients with AF reduced the median length of 
stay in HASU to 7.1 days (IQR=3.1–19.3 days), which is 
not significantly different from patients with stroke who 
are free of AF (P=0.062).
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Among patients with AF who were not anticoagulated 
or deemed unsuitable for anticoagulation on admission, 
91.8% and 75.0% of these patients, respectively, were 
treated with an anticoagulant on discharge (χ2 = 16.2, 
P<0.001).
dIscussIOn
We show that compared with patients without a history of 
AF, those with AF without anticoagulation had a greater 
risk of severe stroke (NIHSS score ≥16), prolonged stay 
in HASU (>3 weeks), risk of early pneumonia, more 
severe disability on discharge (mRS score=4 and 5) and 
inpatient mortality by 1.4-fold to 2.4-fold. Our study of 
the association of AF/anticoagulation therapies with 
pneumonia, UTI and length of stay in HASU is novel. It 
is notable that patients with AF who were anticoagulated 
had a reduced risk of severe stroke and length of stay in a 
HASU to the same level as those who were free from AF. 
The increased risk of severe stroke on arrival, prolonged 
stay in HASU, more severe disability on discharge and 
inpatient mortality in patients with AF without anticoag-
ulation was independent of age, sex, hypertension, CHF, 
diabetes and previous stroke.
Given the growing ageing population,19 disability 
from stroke will continue to impose massive burdens on 
healthcare systems in the foreseeable future worldwide, 
including the UK. There is therefore a need for early 
identification of AF, the biggest treatable risk factor of 
stroke, through systematic screening of at-risk patients in 
the community and intensive treatment for those diag-
nosed with AF.20 However, there is evidence of under-
treatment of AF in the community. In the present study, 
we observed 46.1% of patients with AF who were not on 
anticoagulation on admission. This figure is consistent 
with findings from Bassand et al,21 who observed that 
36.9% of AF patients with CHA2DS2-VASc≥2 were not 
on anticoagulant therapy at inclusion and from Perez 
et al, who found that only 50% of patients with AF who 
were eligible for anticoagulation were given this treat-
ment.22 Similarly, Waldo et al studied 945 patients and 
found that of the 86% of patients who were at high risk 
of stroke, only 55% received warfarin.23 Data from our 
study revealed that most patients with AF who were not 
treated or deemed unsuitable for treatment with an anti-
coagulant on admission were subsequently treated on 
discharge. This suggests that the number of patients who 
are actually contraindicated to anticoagulation is small, 
with most being simply untreated.
Greater collaboration between primary care and 
specialist cardiology services is necessary to improve 
stroke prevention through appropriate treatment of 
AF. The roles of experts such as cardiologists, neurolo-
gists and haematologists are vital in providing specialist 
advice on anticoagulation therapy for patients who pose 
as a treatment dilemma for anticoagulation, such as 
those with a history of bleeding. Other preventable risk 
factors such as obesity, hypertension, dyslipidaemia and 
hyperglycaemia/insulin resistance20 24 25 should also be 
managed intensively.
A number of important findings emerge from the 
present study. All patients with AF, whether treated or 
untreated with an anticoagulant, have increased risks of 
early hospital-acquired infections, disability and mortality. 
This suggests the inherent risk of AF that may be asso-
ciated with other causes of cardiovascular disease leads 
to worse outcomes of stroke.26 In the present study, we 
observed that there was no greater risk for having more 
severe stroke or prolonged stay in HASU among stroke 
patients with AF who were anticoagulated than that of 
those who were free of AF; this evidence reinforces the 
value of intensive treatment of AF with anticoagulants.14
The strengths of the present study include its large 
homogenous cohort of patients derived from one of the 
largest NHS regions in England. The analysis was robustly 
adjusted for age and sex, as well as major chronic condi-
tions known to associate with stroke including hyperten-
sion, CHF, diabetes, previous stroke and in particular 
stroke subtype. The data were collected by healthcare 
providers for the patients using national SSNAP protocol. 
Our study focused on early disability on discharge and 
inpatient mortality. It would be of interest to assess the 
impact of AF anticoagulation status on these outcomes in 
longer term. Although data are derived only from Surrey, 
it is likely to be representative of the rest of the UK as stroke 
prevalence is similar to that of the UK.12 Our study did 
not collect information on types of oral anticoagulants or 
INR that could have some bearing on the outcomes. This 
information is beyond the scope of our study. The length 
of anticoagulation treatment for individual patients was 
not available, but it is likely that it is closely related to 
their age. We chose cut-off point for NIHSS score at 16 
based on previous studies showing that a baseline score 
of ≥16 (moderately severe to severe stroke) was a strong 
predictor of mortality or severe disability,27 while cut-off 
point for mRS score at 4 indicates that, beyond this point, 
functional disability begins to worsen due to increasing 
severity of stroke.28 ‘Prolonged stay’ has variably been 
described.29 In the present study, we defined prolonged 
stay for those who stayed in HASU >3 weeks as this point 
reflects the upper quartile of length of stay in HASU. It 
should be emphasised that these cut-off points tend to 
be arbitrary and the higher the level, the more severe 
is the condition. We have explored various other levels 
including cut-off points for NIHSS score at 12, mRS score 
at 3 and length of stay in HASU at 1 week (50th centile), 
all showing similar patterns of, but weaker, association 
with AF treatment status.
In conclusion, patients with AF, particularly those 
without anticoagulation, are at increased risk of severe 
stroke, associated with prolonged HASU stay and 
increased risk of early infection, disability and mortality.
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